Rhythm Biosciences Expands Reach in Southeast Asia with GeneType Cancer Risk Test
Rhythm Biosciences is poised for significant growth in the Southeast Asian market following the successful completion of its first commercial sale of the geneType cancer risk assessment clinical test in the Philippines. This milestone, achieved just weeks after forging a strategic commercial partnership with Digistain on March 4th, signals a promising new era for early cancer detection and preventative healthcare across the region.
The company’s regional partner, Digistain, a specialist in breast cancer profiling, has not only concluded an initial commercial pilot in the Philippines but is now gearing up to scale sales throughout Southeast Asia. Simultaneously, Digistain is actively establishing pilot programs in several neighbouring countries, laying the groundwork for a comprehensive regional rollout. This initial sale represents a crucial step for Rhythm, providing a solid foundation for increasing testing volumes as distribution networks are strengthened and clinician engagement deepens across the diverse Southeast Asian landscape.
Rhythm Biosciences recognises Southeast Asia as a burgeoning market with immense potential. The region currently exhibits a low penetration rate for advanced cancer risk assessment testing, yet demonstrates a robust demand for earlier detection methods and proactive healthcare solutions.
Dr. Hemmel Amrania, CEO of Digistain Limited, expressed his optimism about the development. “We are delighted to witness this inaugural geneType sale and are confident in the positive impact we can achieve in managing cancer risk within the region,” he stated. The company anticipates further sales in the near future as pilot programs are rolled out in multiple countries, paving the way for a broader commercial launch across Southeast Asia.
Understanding the geneType Cancer Risk Assessment
The majority of cancer cases are classified as sporadic, meaning they occur in individuals without a hereditary predisposition or obvious risk factors. To address this, Rhythm Biosciences developed its innovative geneType genetic risk assessment testing platform. This platform is designed to provide thorough risk evaluations for a spectrum of diseases.
The geneType platform operates by integrating a comprehensive suite of data:
- Clinical Data: Information pertaining to an individual’s current health status and medical history.
- Family History: Details about the prevalence of certain diseases within an individual’s family.
- Genetic Data: Insights derived from genetic testing, identifying predispositions and risk factors at a molecular level.
By combining these diverse data points, the platform delivers personalised health insights across a range of critical conditions. These include, but are not limited to:
- Breast Cancer
- Cardiovascular Disease
- Diabetes
- Colorectal Cancer
- Prostate Cancer
- Melanoma
Genetic testing, such as that offered by geneType, empowers individuals by providing a more nuanced assessment of their cancer risk, extending beyond what can be determined from a simple family history alone. This enhanced understanding can facilitate proactive lifestyle adjustments and the implementation of targeted early screening protocols.
While initial testing volumes are projected to be modest, the company anticipates steady growth as clinician adoption increases and distribution channels mature throughout the region. With its first commercial foothold firmly established in the Philippines, Rhythm Biosciences now possesses a robust platform to effectively scale the geneType offering across the entirety of Southeast Asia, contributing significantly to the advancement of preventative healthcare in the area.
